| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[2] Allopurinol, oral: Krakoff IH. Use of allopurinol in preventing hyperuricemia in leukemia andlymphoma. Cancer. 1966 Nov;19(11):1489-96. https://www.ncbi.nlm.nih.gov/pubmed/5925255
Allopurinol, oral: Coiffier B, Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015 Jun;169(5):661-71. https://www.ncbi.nlm.nih.gov/pubmed/25876990
Allopurinol, oral: South African Medicines Formulary. 12th Edition. Division of Clinical Pharmacology. University of Cape Town, 2016.
Allopurinol, oral: National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine review: Allopurinol, oral for prevention of tumour lysis syndrome in adults, March 2019. http://www.health.gov.za/